Bicycle Therapeutics (BCYC) Cash from Financing Activities (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Cash from Financing Activities came in at -$50000.0 in Q2 2026, down 11.11% YoY from -$56250.0 in Q2 2025, and up 7.41% on a QoQ basis from -$54000.0 in Q1 2026.
Bicycle Therapeutics (BCYC) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Cash from Financing Activities data on file, last reported at -$50000.0 in Q2 2026.
- Quarterly Cash from Financing Activities fell 11.11% year-over-year to -$50000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$149000.0 (up 99.53% YoY) and the FY2025 annual result came in at -$131000.0, down 100.03% from the prior year.
- Cash from Financing Activities grew to -$50000.0 in Q2 2026, from -$54000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $549.6 million in Q2 2024 to a low of -$31.9 million in Q3 2024.
- A 5-year average of $43.1 million and a median of $199000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 147466.67% — and 2024, when it tumbled 113.61%.
- Tracing BCYC's Cash from Financing Activities over 5 years: stood at $5.9 million in 2022, then sank by 93.44% to $386000.0 in 2023, then slumped by 47.41% to $203000.0 in 2024, then slumped by 107.39% to -$15000.0 in 2025, then slumped by 233.33% to -$50000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$50000.0 (Q2 2026), -$54000.0 (Q1 2026), and -$15000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | -50,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50,000.00 |
| Jun 30, 2026 | -50,000.00 |
| Mar 31, 2026 | -54,000.00 |
| Mar 31, 2026 | -54,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Sep 30, 2025 | -30,000.00 |
| Sep 30, 2025 | -30,000.00 |
| Jun 30, 2025 | -45,000.00 |
| Jun 30, 2025 | -45,000.00 |
| Mar 31, 2025 | -41,000.00 |
| Mar 31, 2025 | -41,000.00 |
| Dec 31, 2024 | 203,000.00 |
| Dec 31, 2024 | 203,000.00 |
| Sep 30, 2024 | -31.93 Mn |
| Sep 30, 2024 | -31.93 Mn |
| Jun 30, 2024 | 549.61 Mn |
| Jun 30, 2024 | 549.61 Mn |
| Mar 31, 2024 | 1.87 Mn |
| Mar 31, 2024 | 1.87 Mn |